IBIhor Bekersky

Ihor Bekersky

*This is an algorithmically generated author record based on publicly available information.

Ihor Bekersky has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Robert M. Fielding

    Biologistic Services, Boulder, CO, USA

    4 shared publications
  • Thomas J. Walsh

    Fujisawa Healthcare, Inc., Deerfield, Illinois,1 Biologistic Services, Boulder, Colorado,2 MDS Pharma Services, Lincoln, Nebraska,3 Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland4

    4 shared publications
  • Dawna E. Dressler

    Fujisawa Healthcare, Inc., Deerfield, Illinois,1 Biologistic Services, Boulder, Colorado,2 MDS Pharma Services, Lincoln, Nebraska,3 Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland4

    2 shared publications
  • Donald Buell

    Fujisawa Healthcare Inc

    2 shared publications
  • Donald N. Buell

    Fujisawa Healthcare, Inc., Deerfield, Illinois,1 Biologistic Services, Boulder, Colorado,2 MDS Pharma Services, Lincoln, Nebraska,3 Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland4

    2 shared publications
  • Garry W. Boswell

    Calvert Preclinical Services

    2 shared publications

Latest Publications

  • Plasma Protein Binding of Amphotericin B and Pharmacokinetics of Bound versus Unbound Amphotericin B after Administration of Intravenous Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate

    by Ihor Bekersky, Robert M. Fielding, Dawna E. Dressler, Jean W. Lee, Donald N. Buell, Thomas J. Walsh

    Unilamellar liposomal amphotericin B (AmBisome) (liposomal AMB) reduces the toxicity of this antifungal drug. The unique composition of liposomal AMB stabilizes the liposomes, producing higher sustained drug levels in plasma and reducing renal and hepatic excretion. When liposomes release their drug payload, unbound, protein-bound, and liposomal drug pools may exist simultaneously in the body. To determine the amounts of drug in these pools, we developed a procedure to measure unbound AMB in human plasma by ultrafiltration and then used it to characterize AMB binding in vitro and to assess the pharmacokinetics of nonliposomal pools of AMB in a phase IV study of liposomal AMB and AMB deoxycholate in healthy subjects. We confirmed that AMB is highly bound (>95%) in human plasma and showed that both human serum albumin and α 1 -acid glycoprotein contribute to this binding. AMB binding exhibited an unusual concentration dependence in plasma: the percentage of bound drug increased as the AMB concentration increased. This was attributed to the low solubility of AMB in plasma, which limits the unbound drug concentration to −1 kg −1 ) for both formulations. Unbound drug urinary clearances were equal to the glomerular filtration rate, and tubular transit rates were <16% of the urinary excretion rate, suggesting that net filtration of unbound drug, with little secretion or reabsorption, is the mechanism of renal clearance for both conventional and liposomal AMB in humans. Unbound drug fecal clearances were also similar for the two formulations. Thus, liposomal AMB increases total AMB concentrations while decreasing unbound AMB concentrations in plasma as a result of sequestration of the drug in long-circulating liposomes.


  • Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans

    by Ihor Bekersky, Robert M. Fielding, Dawna E. Dressler, Jean W. Lee, Donald N. Buell, Thomas J. Walsh

    The pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) (liposomal AMB) and the conventional formulation, AMB deoxycholate (AMB-DOC), were compared in a phase IV, open-label, parallel study in healthy volunteers. After a single 2-h infusion of 2 mg of liposomal AMB/kg of body weight or 0.6 mg of AMB-DOC/kg, plasma, urine, and feces were collected for 168 h. The concentrations of AMB were determined by liquid chromatography tandem mass spectrometry (plasma, urine, feces) or high-performance liquid chromatography (HPLC) (plasma). Infusion-related side effects similar to those reported in patients, including nausea and back pain, were observed in both groups. Both formulations had triphasic plasma profiles with long terminal half-lives (liposomal AMB, 152 ± 116 h; AMB-DOC, 127 ± 30 h), but plasma concentrations were higher ( P < 0.01) after administration of liposomal AMB (maximum concentration of drug in serum [ C max ], 22.9 ± 10 μg/ml) than those of AMB-DOC ( C max , 1.4 ± 0.2 μg/ml). Liposomal AMB had a central compartment volume close to that of plasma (50 ± 19 ml/kg) and a volume of distribution at steady state ( V ss ) (774 ± 550 ml/kg) smaller than the V ss of AMB-DOC (1,807 ± 239 ml/kg) ( P < 0.01). Total clearances were similar (approximately 10 ml hr −1 kg −1 ), but renal and fecal clearances of liposomal AMB were 10-fold lower than those of AMB-DOC ( P < 0.01). Two-thirds of the AMB-DOC was excreted unchanged in the urine (20.6%) and feces (42.5%) with >90% accounted for in mass balance calculations at 1 week, suggesting that metabolism plays at most a minor role in AMB elimination. In contrast, <10% of the liposomal AMB was excreted unchanged. No metabolites were observed by HPLC or mass spectrometry. In comparison to AMB-DOC, liposomal AMB produced higher plasma exposures and lower volumes of distribution and markedly decreased the excretion of unchanged drug in urine and feces. Thus, liposomal AMB significantly alters the excretion and mass balance of AMB. The ability of liposomes to sequester drugs in circulating liposomes and within deep tissue compartments may account for these differences.


  • Tacrolimus pharmacology and nonclinical studies: From FK506 to protopic

    by Ihor Bekersky, Herman Lilja, Ira Lawrence

    Tacrolimus (FK506) is a calcineurin inhibitor with potent immunomodulating properties. It has been marketed worldwide since 1993-1994 for the rejection of liver and kidney transplants (Prograf). The pharmacologic properties of tacrolimus resulted in its development as an ointment for the treatment of atopic dermatitis. An outline of nonclinical pharmacology studies that provided a rationale for this development is presented. The key nonclinical toxicology-safety studies that supported clinical efficacy/safety trials are also discussed. Taken collectively, these studies contributed to the marketing approval of 0.03% and 0.1% tacrolimus ointment (Protopic) as a first in class treatment for atopic dermatitis.


  • Safety, Toxicokinetics and Tissue Distribution of Long-Term Intravenous Liposomal Amphotericin B (ambisome®): A 91-day Study in Rats

    by Ihor Bekersky, Garry W. Boswell, Richard Hiles, Robert M. Fielding, Donald Buell, Thomas J. Walsh

    Purpose. Amphotericin B in small, unilamellar liposomes (AmBisome) is safer and produces higher plasma concentrations than other formulations. Because liposomes may increase and prolong tissue...


  • Safety and Toxicokinetics of Intravenous Liposomal Amphotericin B (AmBisome ®) in Beagle Dogs

    by Ihor Bekersky, Garry W. Boswell, Richard Hiles, Robert M. Fielding, Donald Buell, Thomas J. Walsh

    Purpose. Amphotericin B (AmB) in small, unilamellar liposomes (AmBisome ®) has an improved therapeutic index, and altered pharmacokinetics. The repeat-dose safety and toxicokinetic profiles of...